Demographics
| . | Nontransfused (n = 26) . | Transfused (n = 25) . | Control (n = 10) . | ANOVA . |
|---|---|---|---|---|
| Age | 22.7 ± 6.8 | 19.3 ± 4.4 | 22.9 ± 8.0 | 0.06 |
| % Male | 35% | 48% | 50% | 0.54 |
| % Hispanic | 12% | 16% | 10% | 0.85 |
| % On hydroxyurea | 75% | 16% | 0% | <0.0001 |
| % On folic acid | 27% | 28% | 0% | 0.16 |
| % SS | 92% | 100% | 0% | <0.0001 |
| % S-bη thalassemia | 8% | 0% | 0% | <0.0001 |
| Height (cm) | 167.3 ± 9.5 | 162.2 ± 10.4 | 171.6 ± 8.9 | 0.07 |
| Weight (kg) | 64.2 ± 2.2 | 58.8 ± 2.3 | 63.0 ± 3.6 | 0.24 |
| Systolic BP (mm Hg) | 113.2 ± 9.2 | 115.6 ± 6.9 | 116.7 ± 5.9 | 0.25 |
| Diastolic BP (mm Hg) | 61.8 ± 10.0 | 63.3 ± 5.7 | 66.1 ± 8.9 | 0.32 |
| Mean arterial pressure (mm Hg) | 79.3 ± 1.3 | 80.7 ± 1.3 | 85.1 ± 5.2 | 0.06 |
| Body surface area (m2) | 1.72 ± 0.21 | 1.62 ± 0.20 | 1.73 ± 0.16 | 0.15 |
| Body mass index (kg/m2) | 22.8 ± 3.6 | 22.0 ± 2.6 | 21.4 ± 2.6 | 0.45 |
| . | Nontransfused (n = 26) . | Transfused (n = 25) . | Control (n = 10) . | ANOVA . |
|---|---|---|---|---|
| Age | 22.7 ± 6.8 | 19.3 ± 4.4 | 22.9 ± 8.0 | 0.06 |
| % Male | 35% | 48% | 50% | 0.54 |
| % Hispanic | 12% | 16% | 10% | 0.85 |
| % On hydroxyurea | 75% | 16% | 0% | <0.0001 |
| % On folic acid | 27% | 28% | 0% | 0.16 |
| % SS | 92% | 100% | 0% | <0.0001 |
| % S-bη thalassemia | 8% | 0% | 0% | <0.0001 |
| Height (cm) | 167.3 ± 9.5 | 162.2 ± 10.4 | 171.6 ± 8.9 | 0.07 |
| Weight (kg) | 64.2 ± 2.2 | 58.8 ± 2.3 | 63.0 ± 3.6 | 0.24 |
| Systolic BP (mm Hg) | 113.2 ± 9.2 | 115.6 ± 6.9 | 116.7 ± 5.9 | 0.25 |
| Diastolic BP (mm Hg) | 61.8 ± 10.0 | 63.3 ± 5.7 | 66.1 ± 8.9 | 0.32 |
| Mean arterial pressure (mm Hg) | 79.3 ± 1.3 | 80.7 ± 1.3 | 85.1 ± 5.2 | 0.06 |
| Body surface area (m2) | 1.72 ± 0.21 | 1.62 ± 0.20 | 1.73 ± 0.16 | 0.15 |
| Body mass index (kg/m2) | 22.8 ± 3.6 | 22.0 ± 2.6 | 21.4 ± 2.6 | 0.45 |
ANOVA was performed to assess for differences in demographic and baseline vital signs. Bold P values indicate significant differences, P < 0.05.
SS, initial sickle cell genotype.